Apollomics Inc. (NASDAQ:APLM) Sees Significant Decrease in Short Interest

Apollomics Inc. (NASDAQ:APLM) was the target of a large decline in short interest during the month of April. As of April 30th, there was short interest totaling 2,692 shares, a decline of 55.8% from the April 15th total of 6,089 shares. Based on an average daily volume of 4,283 shares, the short-interest ratio is presently 0.6 days. Approximately 0.1% of the company’s stock are short sold.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Apollomics in a research report on Friday, March 27th. Wall Street Zen raised shares of Apollomics from a “sell” rating to a “hold” rating in a report on Saturday, January 17th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Sell”.

Apollomics Stock Up 3.0%

NASDAQ:APLM traded up $0.41 during mid-day trading on Friday, reaching $14.01. 12,028 shares of the company were exchanged, compared to its average volume of 4,589. Apollomics has a 12 month low of $3.66 and a 12 month high of $42.12. The company has a fifty day moving average of $16.17 and a 200 day moving average of $17.52.

Institutional Investors Weigh In On Apollomics

A hedge fund recently bought a new stake in Apollomics stock. Kestra Advisory Services LLC purchased a new stake in Apollomics Inc. (NASDAQ:APLM) in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 4,380 shares of the company’s stock, valued at approximately $82,000. Kestra Advisory Services LLC owned 0.40% of Apollomics as of its most recent SEC filing. Hedge funds and other institutional investors own 19.13% of the company’s stock.

About Apollomics

Apollomics, Inc, a clinical-stage biopharmaceutical company based in Palo Alto, California, focuses on the development of innovative targeted therapies and immuno-oncology agents for the treatment of cancer. The company’s research and development efforts center on small molecule inhibitors and monoclonal antibodies designed to address key pathways involved in tumor growth and immune evasion. Its lead asset, dalpiciclib (formerly SHP654), is a selective oral CDK4/6 inhibitor in Phase III trials for metastatic breast cancer, and Apollomics holds a number of additional early-stage programs targeting solid tumors and hematologic malignancies.

Founded in 2015, Apollomics has established research and clinical collaboration networks across North America, China and Europe.